Topical Steroids — Fast Genomic Anti-Inflammatory Action
Placeholder: steroids bind glucocorticoid receptors and shut down inflammation quickly.
- 1–3 days: Onset time (placeholder value)
- GR: Receptor (glucocorticoid receptor)
- 7: Potency classes (placeholder classes)
- 1–2 wk: Typical course (placeholder duration)
Genomic anti-inflammatory pathway
Placeholder: steroid diffuses into cell, binds GR, alters gene transcription to cut cytokines.
Tacrolimus & Pimecrolimus — Blocking T-Cell Activation
Placeholder: TCIs inhibit calcineurin, blocking IL-2 transcription in T-cells.
- Calcineurin: Target (placeholder enzyme)
- T-cell: Cell type (placeholder target cell)
- ~1 week: Onset time (placeholder value)
- Yes: Steroid-sparing (placeholder note)
T-cell calcineurin blockade
Placeholder: drug binds FKBP, inhibits calcineurin, prevents NFAT-driven cytokine genes.
Comparing Speed of Anti-Inflammatory Onset
Placeholder: steroids relieve symptoms noticeably faster than calcineurin inhibitors.
- Fast: Steroid onset (placeholder comparison)
- Slower: TCI onset (placeholder comparison)
- ~2 wk: Crossover point (placeholder value)
- Variable: Patient adherence (placeholder note)
Onset curve comparison
Placeholder: onset curves diverge early then converge over continued use.
Skin Atrophy vs Application-Site Burning
Placeholder: steroids risk thinning skin, TCIs risk transient burning sensation.
- Rises w/ use: Atrophy risk (steroid) (placeholder trend)
- Early, fades: Burning risk (TCI) (placeholder trend)
- Partial: Reversibility (placeholder note)
- Duration/site: Risk driver (placeholder note)
Side effect trade-off
Placeholder: longer steroid use raises atrophy risk on thin skin; TCIs favor short burning instead.
Choosing Therapy for Face, Eyelids, and Skin Folds
Placeholder: sensitive sites often favor calcineurin inhibitors for long-term maintenance.
- TCI preferred: Face/eyelid pick (placeholder guidance)
- Steroid ok: Body/thick skin (placeholder guidance)
- TCI favored: Maintenance use (placeholder guidance)
- Regular: Monitoring (placeholder note)
Site-specific long-term strategy
Placeholder: match agent to skin site and treatment duration for best long-term outcome.
Placeholder key insight: sensitive-site long-term care generally favors calcineurin inhibitors.